Association between the CHEK2*1100delC germ line mutation and estrogen receptor status

G.H. de Bock, M.J. Mourits, M. Schutte, E.M. Krol-Warmerdam, C. Seynaeve, J. Blom, C.T. Brekelmans, H. Meijers-Heijboer, C.J. van Asperen, C.J. Cornelisse, P. Devilee, R.A. Tollenaar, J.G. Klijn

OnderzoeksoutputAcademic

15 Citaten (Scopus)

Samenvatting

Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status
Originele taal-2English
Pagina's (van-tot)552-555
Aantal pagina's4
TijdschriftInternational Journal of Gynecological Cancer
Volume16 Suppl 2
StatusPublished - 2006

Citeer dit